Patients with bipolar disorder experienced significant reductions in sleep efficiency, which was not the case in patients with schizophrenia, although effect sizes for bipolar disorder were smaller overall.
In patients with schizophrenia, cannabis use may be linked to elevated risk of all-cause mortality but decreased risk of mortality from digestive organ diseases.
Given the increased risk for opioid-related problems among patients with psychiatric diagnoses, the investigators advised a more cautious approach to prescribing that integrates expertise from mental health clinicians.
Among patients with schizophrenia, long-term antipsychotic use does not appear to increase severe physical morbidity or somatic hospitalization, and mortality is lower for antipsychotic use compared with no use.
The findings suggest that factors such as antipsychotic treatment, diet, or lifestyle may contribute to weight gain in patients with long-term disease.
Researchers conducted a case-control study to examine the associations between polygenic risk scores for schizophrenia and other mental disorders with the development of cannabis use disorder.
The investigators noted that “modifications in brain circuitry in service of developing more complex brain functionality in humans may have potentially also shaped aspects of human-specific brain dysfunction.
Overall, no significant relationships between task performance and gray matter volume were observed in the clinical high-risk group.
Prior research has demonstrated a link between schizophrenia and risk factors for lung cancer, particularly smoking, obesity, physical inactivity, and metabolic disorders.
Adverse cardiometabolic outcomes were more commonly observed among patients from black and ethnic minority groups compared with white patients.
